These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 20190566)

  • 1. The VEGF family in cancer and antibody-based strategies for their inhibition.
    Sullivan LA; Brekken RA
    MAbs; 2010; 2(2):165-75. PubMed ID: 20190566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
    Adjei AA
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S74-8. PubMed ID: 17382028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF inhibitors in cancer therapy.
    Cardones AR; Banez LL
    Curr Pharm Des; 2006; 12(3):387-94. PubMed ID: 16454752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
    Homsi J; Daud AI
    Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
    Schlaeppi JM; Wood JM
    Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis in Colorectal Cancer: Antibodies.
    Chan E
    Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
    Grépin R; Pagès G
    J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenesis, anti-VEGF(R) and outlook.
    Petersen I
    Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y; Liu Q
    Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor and bevacitumab in breast cancer.
    Bando H
    Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.
    Wahl O; Oswald M; Tretzel L; Herres E; Arend J; Efferth T
    Curr Med Chem; 2011; 18(21):3136-55. PubMed ID: 21671856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
    Ellis LM; Rosen L; Gordon MS
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.